Author:
Ikuta Katsuya,Ito Hiroaki,Takahashi Keiji,Masaki Shinya,Terauchi Masaru,Suzuki Yasuo
Funder
Zeria Phamaceutical Co., Ltd.
Zeria Phamaceutical Co. Ltd.
Publisher
Springer Science and Business Media LLC
Reference11 articles.
1. World Health Organization. Iron deficiency anemia-assessment, prevention, and control. A guide for program managers. 2001. Report No.: Document WHO/NHD/01.3.
2. Harigae H. Iron metabolism and related diseases: an overview. Int J Hematol. 2018;107:5–6.
3. Adamson JW. Iron deficiency and other hypoproliferative anemias. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 18th ed. New York: McGraw-Hill Companies; 2013. pp. 844–51.
4. Cada DJ, Levien TL, Baker DE. Ferric carboxymaltose. Hosp Pharm. 2014;49:52–69.
5. Ikuta K, Shimura A, Terauchi M, Yoshii K, Kawabata Y. Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia. Int J Hematol. 2018;107:519–27.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献